心肾综合征患者高钾血症的优化管理
本文综述心肾综合征患者高钾血症的患病率与临床意义,指出RAASi是心血管疾病尤其心衰的标准治疗,但高钾风险常导致减量或停药,而停药与HFREF患者出院后死亡和再住院率升高相关。文章汇总新型降钾治疗策略,以维持血钾正常并支持RAASi持续使用。
要点
- RAASi在HFREF(射血分数降低的心衰)症状II-IV级为IA类推荐,可降低全因死亡和心衰住院。
- 肾功能减退者RAASi相关高钾风险增加,高钾常导致RAASi减量或停药。
- HFREF住院患者停用RAASi与出院后死亡和再住院率升高相关,需有效降钾以维持RAASi治疗。
核心结论
- 心肾综合征合并高钾风险患者需有效降低血钾并维持血钾正常,以保障RAASi持续治疗并最大化获益。
研究设计与样本
- 本文为综述,汇总心肾综合征患者高钾血症的患病率、临床意义及新型治疗管理策略。
主要发现
- RAASi在HFREF症状II-IV级获欧洲心脏病学会和美国心脏病学会/美国心脏协会IA类推荐,基于降低全因死亡和心衰住院的强临床获益。
- 接受ACEI或ARB背景治疗者加用盐皮质激素受体拮抗剂可能增加高钾风险,尤其肾功能减退者。
- HFREF住院患者停用RAASi与出院后死亡率和再住院率升高相关,而RAASi优化剂量显著减少中位住院时间、门诊就诊及相关费用。
临床怎么用
- 对心肾综合征高钾风险患者应积极降钾维持血钾正常,避免RAASi减量或停药以保留其获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Renin-angiotensin-aldosterone system inhibitors (RAASi) are now a standard treatment in most patients with cardiovascular disease, especially in those with heart failure (HF). The European Society of Cardiology and the American College of Cardiology/American Heart Association gave a Class IA recommendation for the use of RAASi in the treatment of Classes II-IV symptomatic HF with reduced ejection fraction (HFREF), based on their strong clinical benefits of lowering all-cause mortality and HF hospitalizations in these subjects. However, RAASi therapy or adding mineralocorticoid receptor antagonists in subjects receiving background angiotensin-converting enzyme inhibitors or angiotensin receptor blockers may be associated with an increased risk of hyperkalemia (HK), especially in those with reduced kidney function. As a result, a significant proportion of these subjects either have RAASi dose reduced or more often discontinued when they develop HK. Discontinuation of RAASi in patients hospitalized with HFREF was associated with higher postdischarge mortality and rehospitalization rates, while optimal dosing of RAASi significantly reduced median hospital stays, outpatient visits and related costs. Thus, effective treatment is required to lower potassium level and maintain normokalemia in subjects with HF and reduced kidney disease who develop or are at risk of HK, thus enabling them to continue their RAASi therapy and maximize benefits from RAASi. In this review, we provide an up-to-date review of the prevalence and significance of HK in patients with cardiorenal syndrome, as well as their optimal management of HK with recent novel therapies.
引用
- Wang AY. Optimally managing hyperkalemia in patients with cardiorenal syndrome. Nephrol Dial Transplant. 2019. PMID: 31800079. doi:10.1093/ndt/gfz225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。